We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares
CYAD

Delisted

CYAD was delisted on the 18th of May, 2023.

Back to rankings

9 hedge funds and large institutions have $9.23M invested in Celyad Oncology SA American Depositary Shares in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

19% more capital invested

Capital invested by funds: $7.74M → $9.23M (+$1.49M)

13% more funds holding

Funds holding: 8 → 9 (+1)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$101K
2
UBS Group
UBS Group
Switzerland
+$5.14K
3
JP Morgan Chase
JP Morgan Chase
New York
+$39
4
RCA
Ranch Capital Advisors
Florida
+$39

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$2.03M
2
Morgan Stanley
Morgan Stanley
New York
-$75.6K
3
Wells Fargo
Wells Fargo
California
-$9.76K
4
Millennium Management
Millennium Management
New York
-$8.44K
5
Deutsche Bank
Deutsche Bank
Germany
-$4K

CYAD Hedge Fund Activity: Q2 2020 in Review

9 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2020, worth a combined $9.23M — up 19% from $7.74M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CYAD positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $101K. The largest seller was Victory Capital Management, cutting an estimated $2.03M.

  • 9 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2020, up from 8 in Q1 2020.
  • Funds reported $9.23M of Celyad Oncology SA American Depositary Shares stock for Q2 2020, up 19% quarter-over-quarter.
  • 3 funds opened new Celyad Oncology SA American Depositary Shares positions in Q2 2020 and 2 closed out, a net change of +1 holder.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2020 was Renaissance Technologies, an estimated $101K added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q2 2020 was Victory Capital Management, an estimated $2.03M sold.

Based on aggregated 13F filings for Q2 2020.